Global Distribution and Characteristics of Research Facilities Participating in Phase III Oncology Trials
Cancer Medicine · 2026-11 · 15 (11)
DOI: 10.1002/cam4.72418 ↗Abstract
ABSTRACT Background Phase III clinical trials offer patients access to emerging therapies, yet geographical access varies significantly. The profile of research facilities conducting such trials can provide insights into global disparities. Methods We extracted all research sites within recruiting Phase III cancer interventional trials from the ClinicalTrials.gov database on July 23, 2024. Address components were combined and queried through the Google Maps API for standardized identification. We compared research facilities' number, density (per 1 M people), and portfolio of trials across World Bank regions and estimated the elasticity coefficient [β] of trials and research facilities per country with log–log linear models. Results Of 77,625 listed sites from 1287 trials, 64,018 (82.5%) were mapped to 6634 unique research facilities across 84 countries. The number of research facilities and trials by country were strongly correlated (R 2 = 0.86, p value < 0.001, β = 0.95, 95% CI 0.87–1.04). The United States and China had the largest number of facilities (2626, 39.6%) and trials (624, 48.5%) respectively. The 100 largest research facilities in size were from high‐income countries (HIC) or China, and 16/20 (80%) top countries by density were located in Europe and Central Asia. Latin America and Caribbean, South Asia, and Sub‐Saharan Africa had high proportion of facilities running exclusively multiregional (> 93%, p value < 0.001), industry‐sponsored (> 90%, p value < 0.001), and systemic therapy trials (> 80%, p value < 0.001). Conclusions The number of research facilities is strongly associated with the volume of cancer trials across countries. Outside HICs, research facilities were less numerous, focused on systemic therapies, and frequently reliant on industry‐sponsored, multiregional trials.
EUVIMED